AMAG Pharmaceuticals RSI
Quel est le RSI de AMAG Pharmaceuticals?
Le RSI de AMAG Pharmaceuticals, Inc. est 97.78
Quelle est la définition de RSI?
L'indice de force relative (RSI 14) est un indicateur de dynamique qui compare l'ampleur des gains et des pertes sur une période donnée afin de mesurer la vitesse et l'évolution des mouvements de prix d'un titre.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI des entreprises dans Health Care secteur sur NASDAQ par rapport à AMAG Pharmaceuticals
Que fait AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Entreprises avec rsi similaire à AMAG Pharmaceuticals
- 6D Global Technologies a RSI de 97.61
- MyFiziq a RSI de 97.65
- Bio-Rad Laboratories a RSI de 97.73
- Luen Wong a RSI de 97.75
- Cadeler A/S a RSI de 97.76
- Duesenberg Technologies a RSI de 97.76
- AMAG Pharmaceuticals a RSI de 97.78
- Arq a RSI de 97.79
- Tritent International a RSI de 97.82
- CenturyLink a RSI de 97.83
- China Biologic Products Inc a RSI de 97.83
- Better Capital PCC 2009 a RSI de 97.88
- Elixinol Global a RSI de 97.98